Health & Fitness
Health and Fitness
Health and Fitness
Fri, February 6, 2009
Thu, February 5, 2009 Targacept to Report Fourth Quarter and 2008 Financial Results on February 12, 2009
WINSTON-SALEM, N.C.--([ BUSINESS WIRE ])--Targacept, Inc. (NASDAQ: [ TRGT ]), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will report financial results for the fourth quarter and year ended December 31, 2008 on Thursday, February 12, 2009, after the U.S. financial markets close.
Management will discuss the fourth quarter and year end results, provide an update on the company's product development programs and business activities and discuss expectations for the future via conference call at 5:00 p.m. Eastern Standard Time on Thursday, February 12, 2009. The conference call may be accessed by dialing 866-783-2137 for domestic participants and 857-350-1596 for international callers (reference passcode 29165052). A replay of the conference call may be accessed from 9:00 p.m. Eastern Standard Time on February 12, 2009 through February 26, 2009 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 48125665).
A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept's website, [ www.targacept.com ]. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept's website for at least two weeks following the call.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease, attention deficit/hyperactivity disorder, major depressive disorder, cognitive dysfunction in schizophrenia and pain, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at [ www.targacept.com ].
